EI
PRTK

EAM Investors’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

EAM Investors’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-170,142
Closed -$1.06M – 470
2020
Q4 		$1.06M Buy
+170,142
New +$1M 0.17% 261
2017
Q4 		– Sell
-77,885
Closed -$1.96M – 365
2017
Q3 		$1.96M Sell
77,885
-66,137
-46% -$1.54M 0.26% 201
2017
Q2 		$3.47M Buy
+144,022
New +$3.18M 0.57% 45

Other funds holding PRTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM Investors's PRTK Position: Q1 2021 in Review

EAM Investors sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2021, closing a stake of 170,142 shares — an estimated $1.06M sold.

EAM Investors first reported a position in PRTK in Q2 2017 and held it in 3 quarters. The position peaked at $3.47M in Q2 2017. 107 funds tracked by Wall St. Rank hold PRTK as of Q1 2021.

  • EAM Investors reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
  • EAM Investors sold 170,142 Paratek Pharmaceuticals, Inc. shares in Q1 2021, an estimated $1.06M.
  • EAM Investors first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2017 and held it in 3 quarters.
  • EAM Investors's Paratek Pharmaceuticals, Inc. position peaked at $3.47M in Q2 2017.
  • 107 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2021.

Based on EAM Investors's 13F filing for Q1 2021, filed 11 May 2021.